==== Front PLoS One PLoS One plos PLOS ONE 1932-6203 Public Library of Science San Francisco, CA USA 10.1371/journal.pone.0288159 PONE-D-23-05701 Research Article Medicine and Health Sciences Mental Health and Psychiatry Mood Disorders Depression Biology and Life Sciences Biochemistry Hormones Peptide Hormones Leptin Biology and Life Sciences Physiology Immune Physiology Cytokines Biology and Life Sciences Immunology Immune System Innate Immune System Cytokines Medicine and Health Sciences Immunology Immune System Innate Immune System Cytokines Biology and Life Sciences Developmental Biology Molecular Development Cytokines Medicine and Health Sciences Pathology and Laboratory Medicine Research and Analysis Methods Research Design Case-Control Studies Research and Analysis Methods Immunologic Techniques Immunoassays Enzyme-Linked Immunoassays Medicine and Health Sciences Epidemiology Medical Risk Factors Medicine and Health Sciences Medical Conditions Inflammatory Diseases Association of reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study Reduced serum EGF levels are associated with major depression https://orcid.org/0000-0003-1251-2284 Sohan Md. Conceptualization Data curation Formal analysis Methodology Writing – original draft 1 Qusar M. M. A. Shalahuddin Data curation Writing – review & editing 2 Shahriar Mohammad Investigation Project administration 1 Islam Sardar Mohammad Ashraful Investigation Project administration 1 Bhuiyan Mohiuddin Ahmed Investigation Project administration 1 https://orcid.org/0000-0003-2820-3144 Islam Md. Rabiul Conceptualization Formal analysis Methodology Supervision Writing – review & editing 1 * 1 Department of Pharmacy, University of Asia Pacific, Farmgate, Dhaka, Bangladesh 2 Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Shahabagh, Dhaka, Bangladesh Molla Md Maruf Ahmed Editor SUNY Upstate Medical University: State University of New York Upstate Medical University, UNITED STATES Competing Interests: The authors have declared that no competing interests exist. * E-mail: robi.ayaan@gmail.com 3 7 2023 2023 18 7 e028815927 2 2023 20 6 2023 © 2023 Sohan et al 2023 Sohan et al https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Major depressive disorder (MDD) is a heterogeneous mental disorder having a very diverse course and causing a significant changes in daily life. Though the exact pathophysiology of depression is still not known, an alteration in the serum levels of cytokines and neurotrophic factors was seen in MDD subjects. In this study, we compared the serum levels of ‘pro-inflammatory cytokine leptin and neurotrophic factor EGF’ in healthy controls (HCs) and MDD patients. To make the findings more accurate, we eventually looked for a correlation between altered serum leptin and EGF levels and the severity of the disease condition. Methods For this case-control study, about 205 MDD patients were enrolled from the Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Dhaka, and about 195 HCs were enrolled from various parts of Dhaka. The DSM-5 was utilized to evaluate and diagnose the participants. The HAM-D 17 scale was used to measure the severity of depression. After collecting blood samples, they were centrifuged to produce clear serum samples. These serum samples were analyzed using enzyme-linked immunosorbent assay (ELISA) kits to measure serum leptin and EGF levels. Results We observed lowered serum EGF levels in MDD patients compared to HCs (524.70 ± 27.25 pg/ml vs. 672.52 ± 49.64 pg/ml, p = 0.009), and HAM-D score was elevated in MDD patients compared to HCs (17.17 ± 0.56 vs. 2.49 ± 0.43, p<0.001). But no correlation was established between serum EGF levels and the severity of depression. However, no significant differences were observed between MDD patients and HCs in the case of serum leptin levels (p = 0.231). Conclusion Our study findings suggest that reduced serum EGF levels have an impact on the pathogenesis of depression. But as per our investigation, the severity of depression is not correlated with altered EGF levels. Our findings regarding the association of EGF with MDD would help to use EGF as a risk indicator of depression. We suggest further clinical investigations to determine the precise function of leptin and EGF in depression. The author(s) received no specific funding for this work. Data AvailabilityAll relevant data are within the paper. Data Availability All relevant data are within the paper. ==== Body pmcIntroduction MDD is a heterogeneous disorder with a quite varied course and is distinguished by a low mood, lowered interest, and poor cognitive abilities [1, 2]. MDD is responsible for causing a drastic change in everyday life. At least a few psychological and physiological abnormalities, such as alteration in sleep, altered appetite, low sexual urges, the inability to enjoy activities at work, loss of enjoyment with friends, weeping, suicidal ideation, and a slowdown of speech, are all associated with MDD. The fundamental criteria for diagnosis of MDD are that such alterations must cause significant disruptions to work and family life for at least two weeks. In the development of MDD, a lot of factors can be related. According to an estimation, about 35% of MDD is genetically predisposed, which means that genetic factors may be involved in how the disease develops [1, 3–6]. Moreover, a variety of social factors, such as socioeconomic impression, lack of social support, along with poor educational background, considerably raise the risk of MDD in both males and females [7]. On the one hand, trauma regarding ’physical, emotional, or sexual abuse during childhood might also be a contributing factor to MDD [8]. In contrast, MDD is the second most significant medical condition when contributing to the burden of chronic diseases. Heart disease, diabetes mellitus, and stroke are all illnesses linked to an increased chance of developing [2, 9, 10]. It has been demonstrated in a study that more than 26.1% of females and 14.7% of males are dealing with depression during their lifespan in the USA [11]. This finding supports the conclusion made in a study that women are roughly twice as likely as males to experience MDD [12]. According to a survey report, the prevalence of MDD in a calendar year varied by country, which is about 2.20% and 10.40% in Japan and Brazil, respectively [13]. Another study has revealed that people from middle-income nations are less affected by MDD than people from high-income nations. Furthermore, it has also been found that the chance to affect by MDD is decreased with age in people from high-income countries [14]. In terms of Bangladesh, a study stated that the prevalence of depressive disorder was about 4.4% [15]. MDD is also linked to causing suicide. People with MDD are at risk of dying by suicide 20 times more than the general population [16, 17]. As MDD is one of the leading causes of the deterioration of personal and social life, thus knowledge about the progression of MDD is essential. It has been challenging to understand the pathophysiology of MDD because of the clinical variability of the condition. Several hypotheses have been proposed till now about the development and progression of major depression. All of those hypotheses are supported by investigations regarding mental stress and findings about an increase in the level of hormones released due to stress like a CRH (corticotropin-releasing hormone) [1, 18], alteration in the levels of inhibitory and excitatory neurotransmitters such as GABA, glutamate [19], reduction in the availability of neurotransmitters, e.g., dopamine, noradrenaline, and serotonin in the synaptic cleft [1, 20], respectively. Also, it has been observed that the neurotrophic factors and circadian cycle have a role in the pathophysiology of depression [1, 21]. The neurotrophic factors have been found at a decreased level, usually in the case of MDD patients, along with animal models with MDD [22]. Thus, it is universally acknowledged that an imbalance in neurochemicals causes the pathophysiology of MDD. However, a change in neurochemical structure is also associated with major depression [23–25]. For the genesis of depression, the involvement of inflammatory cytokines is also demonstrated in many studies. By influencing neural activity either directly or indirectly, inflammatory cytokines raise the likelihood of mood disorders, according to growing evidence. For instance, IFN-α a cytokine involved with the pathogenesis of depression by affecting the frontal lobe, dopaminergic, serotonergic, and glutamatergic activity [26–29]. According to the involvement of cytokines with the inflammatory process, they are classified as pro-inflammatory and anti-inflammatory [17]. Several studies have been conducted with pro and anti-inflammatory cytokines separately to understand the association of cytokines more precisely. It has been depicted that, an elevation in the levels of a few pro-inflammatory cytokines and a reduction in the levels of a few anti-inflammatory cytokines may be responsible for causing depression [30–33]. Thus, it can be concluded that alterations in the levels of cytokines and neurotrophic factors might be involved with the pathophysiology of depression. Leptin and Epidermal growth factor (EGF) are neurochemicals that may have an impact on the development of MDD. The pro-inflammatory cytokine leptin, produced by adipocytes, plays a role in immune system functions. As a cytokine, it can influence thymic homeostasis and affect the secretion of TNF-α and IL-1, which are separately involved with the progression of depression [34–37]. Many clinical studies have looked into the connection between leptin and depression. However, results from all of these investigations indicate a discrepancy. Initially, studies have concluded after conducting case-control studies that leptin levels remain in low levels in depressive patients compared with healthy subjects [38–40]. In contrast, higher leptin levels were also found in MDD patients [41, 42]. Another case-control study showed that major depressive individuals exhibited higher leptin levels at night. The study hypothesized that elevated leptin levels at night increase CRH secretion, a hormone associated with the progression of depression [43]. In contrast, few case-control studies have not found any significant change in leptin levels in MDD patients. A meta-analysis also supports the inconsistent involvement of leptin with major depression [44–46]. In terms of EGF, it acts as a neurotrophic factor and has contributed to MDD development. A preliminary investigation has been conducted among MDD individuals to determine the levels of neurotrophic factors. It has been depicted that the plasma levels of EGF have decreased when compared to healthy controls [22]. In comparison, an increase in EGF levels was found in another case-control study [47]. Moreover, another study concluded that no significant difference was found after comparing plasma concentration of EGF levels between patients and control groups [48]. Thus, the involvement of leptin and EGF with MDD still needs to be clarified as changes in leptin and EGF plasma levels between patient and control groups exhibit discrepancies. As leptin acts as a proinflammatory cytokine, it can potentially induce the inflammatory process. It involves with depression in a different manner compared to EGF, as it acts as a neurotrophic factor. In this study, we aimed to investigate the association of leptin and EGF with MDD simultaneously. Thus, it will help to understand the pathophysiology of MDD from two different points of view. In order to draw a clear line between the involvement of leptin and EGF serum levels with MDD, we aimed to inspect leptin and EGF levels in MDD patients and healthy controls. In addition, if any variation would be discovered, we sought to look into the relationship between changed serum leptin and EGF levels and the severity of depression. Methods Study participants We enrolled 205 individuals with MDD and 195 healthy controls (HCs) in this case-control study. Patients having MDD were enlisted from the Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. From all around Dhaka, HCs were recruited. Regarding sex and age, the HCs and MDD patients were almost identical. The DSM-5 was used by a professional psychiatrist to diagnose MDD patients. In order to evaluate the severity of depression, the HAM-D 17 scale was used. Information regarding socio-demographic variables and any other mental illness of MDD patients and HCs was collected by using a pre-structured questionnaire. In our investigation, we included participants ranging from 18 to 60 years old. Furthermore, those MDD patients were enrolled in whom depressive symptoms had been present for at least two weeks. We did not include participants who had ever experienced heart disease, hepatic failure, epilepsy, or renal failure. Participants undergoing antidepressant treatments that could affect the concentration of serum leptin and EGF levels were also omitted. Furthermore, those with further comorbid mental problems, chronic organic disorders, a very high BMI, substance use, or dependency were omitted from the study. HAM-D 17 scale To measure the severity of major depressive disorder, the 17 item Hamilton Depression Rating Scale (HAM-D) was utilized. According to this scale, the total score is classified into four distinct categories: “no depression” when the score is between 0 to 7, “mild depression” when the score is between 8 to 16, “moderate depression” when the score is between 17 to 23, “severe depression” when the score is ≥24 [49]. Blood sample collection After collecting 10ml of blood from the cephalic vein of study subjects, blood was placed in centrifuge tubes. The serum was collected after centrifuging each sample at 1000 x g for 15 minutes and then stored at -80°C for future analysis. Analysis of serum samples We utilized commercially available enzyme-linked immunosorbent assay (ELISA) kits to assess the serum levels of leptin and EGF based on the instructions made by the manufacturer (Boster Biological Technology, USA). The procedures are the same for leptin and EGF analysis. We used marker-specific reagents where necessary. Initially, the serum samples were brought to room temperature and vortexed to create a homogeneous mixture. Briefly, about 100μl of (diluted) standards and samples were placed in each well of microplates, where each well was coated with the capture antibody. After incubating microplates (sealed with plate sealer) at 37°C for one and half an hour, the liquid was removed to put 100μl of detection antibodies in wells. Again, the plates were incubated for one hour following the same incubation conditions, and after then, the liquids were discarded. Before putting 100μl of the avidin-biotin-peroxidase complex in each well, plates were washed three times using phosphate buffer solution. Then, the plates were incubated for 40 minutes at room temperature; the plates were rewashed using a wash buffer five consecutive times. After then, about 90μl of the color-developing agent was added to each well and then incubated each plate at room temperature in a dark area. In the end, about 100μl of stop solution was added, and within 30 minutes, absorbance was measured at 450nm using a microplate reader. The serum levels of leptin and EGF in MDD and HCs were calculated using a marker-specific standard curve and expressed in ng/ml and pg/ml, respectively. Statistical analysis IBM SPSS (version 25.0) and Microsoft Excel 2019 were utilized to complete the necessary analysis. The Independent sample t-test and chi-square test were applied to differentiate between the groups for variables (continuous and categorical). The box-plot graph 1 demonstrated the differences in the blood EGF concentrations, and box-plot graph 2 demonstrated the differences in the serum leptin concentrations of HCs and MDD patients. The distribution of EGF and leptin levels in MDD patients against the HAM-D score was depicted in scatterplot graph 1 and scatterplot graph 2, respectively. The socio-demographic factors of the study subjects were subjected to descriptive statistical calculations, and the findings were presented as mean ± standard error mean (SEM). The findings were considered statistically significant when the p-value was less than 0.05. Ethics The Research Ethics Committee (REC) of the University of Asia Pacific approved the research protocol (Ref: UAP/REC/2022/206). All participants were informed regarding the study’s purpose, and their written consent was acquired. We conducted each investigation in accordance with the Declaration of Helsinki. Results Characteristics of study population The socio-demarchic and biographical characteristics of the study participants are demonstrated in Table 1. No significant difference was observed between MDD patients and HCs in terms of age (p = 0.901) as the number of males and females was almost equal in both groups. Apart from that, significant differences were observed in case of marital status, educational level, occupation, economic impression, area of residence, previous history and family history of MDD. 10.1371/journal.pone.0288159.t001 Table 1 Socio-demographic profile of the study population. Characteristics MDD patients (n = 205) Mean ± SEM Healthy controls (n = 195) Mean ± SEM p-value Age in years 30.80 ± 0.671 30.08 ± 0.663 0.901     18–25 76 (37.07%) 67 (34.36%)     26–35 75 (36.59%) 73 (37.44%)     36–45 36 (17.56%) 39 (20.00%)     46–60 18 (8.78%) 16 (8.21%) Sex 0.754     Male 65 (31.71%) 59 (30.26%)     Female 140 (68.29%) 136 (69.74%) Marital Status 0.001     Married 134 (65.37%) 96 (49.23%)     Unmarried 71 (34.63) 99 (50.77%) BMI (kg/m2) 23.57 ± 0.308 24.45 ± 0.261 0.006     Below 18.5 (CED) 21 (10.24%) 5 (2.56%)     18.5–25 (normal) 113 (55.12%) 109 (55.90)     Above 25 (obese) 71 (34.63%) 81 (41.54%) Education level 0.020     Illiterate 16 (7.80%) 15 (7.69%)     Primary level 50 (24.39%) 29 (14.87%)     Secondary level 77 (37.56%) 66 (43.59%)     Graduate and above 62 (30.24%) 85 (56.32%) Occupation < 0.001     Business 7 (3.41%) 4 (2.05%)     Service 34 (16.59%) 57 (29.23%)     Housewife 46 (22.44%) 23 (11.79%)     Unemployed 56 (27.32%) 36 (18.46%)     Student 27 (13.17%) 59 (30.26%)     Others 35 (17.07%) 16 (8.21%) Economic impression < 0.001     High 24 (11.71%) 81 (41.54%)     Medium 148 (72.20%) 108 (55.38%)     Low 33 (16.10%) 6 (3.08%) Smoking habit 0.875     Non-smoker 187 (91.22%) 177 (90.77%)     Smoker 18 (8.77%) 18 (9.23%) Residence area < 0.001     Rural 87 (42.44%) 45 (23.08%)     Urban 118 (57.56%) 150 (76.92%) Previous history of MDD < 0.001     Yes 111 (54.15%) 0 (0.00%)     No 94 (45.85%) 195 (100.00%) Family history of MDD < 0.001     Yes 58 (28.29%) 2 (1.03%)     No 147 (71.71%) 193 (98.97%) Abbreviations: BMI, body mass index; CED, chronic energy deficiency; MDD, major depressive disorder; SEM, standard error mean. (p-value was determined by chi-square test) Clinical profile and laboratory findings The clinical profile and laboratory findings are presented in Table 2. The DSM-5 score was 7.49 ± 0.087 among MDD patients, and the DSM-5 score was 1.32 ± 0.098 in HCs (p<0.001). The HAM-D score was 17.97 ± 0.358 and 2.25 ± 0.209 in MDD and healthy subjects, respectively (p<0.001). Lower leptin levels were observed in MDD patients (62.83 ± 4.28 ng/ml) in comparison with HCs (69.74 ± 3.85 ng/ml), p = 0.231. The serum levels of EGF were 524.70 ± 27.25 pg/ml in MDD patients and 672.52 ± 49.64 pg/ml in HCs (p = 0.009). Moreover, the boxplots exhibit the distribution of serum EGF and leptin levels in MDD patients and HCs (Fig 1). It shows higher EGF and leptin levels in HCs than in MDD patients. On the other hand, sex-specific scatter plots depict the distribution of serum EGF and leptin levels in males and females with MDD against the HAM-D score (Fig 2). 10.1371/journal.pone.0288159.g001 Fig 1 Distribution of serum EGF and leptin levels in MDD patients and healthy controls. Boxplot graphs showing the median, maximum and minimum value range. 10.1371/journal.pone.0288159.g002 Fig 2 Sex-specific scatter plot graphs showing distribution of EGF and leptin levels against HAM-D scores of MDD patients. 10.1371/journal.pone.0288159.t002 Table 2 Clinical profile and laboratory findings of the study population. Parameters MDD patients (n = 205) Mean ± SEM Healthy controls (n = 195) Mean ± SEM p-value Age (years) 30.80 ± 0.671 30.96 ± 0.663 0.901     Male (P/C:65/59) 29.95 ± 1.23 31.41 ± 1.24 0.407     Female (P/C:140/136) 31.19 ± 0.81 30.76 ± 0.79 0.703 BMI (Kg/m2) 23.57 ± 0.308 24.45 ± 0.261 0.006     Male (P/C:65/59) 23.42 ± 0.55 24.55 ± 0.45 0.118     Female (P/C:140/136) 23.64 ± 0.37 24.41 ± 0.32 0.119 DSM-5 score 7.49 ± 0.087 1.32 ± 0.098 < 0.001     Male (P/C:65/59) 7.60 ± 0.16 1.37 ± 0.18 < 0.001     Female (P/C:140/136) 7.44 ± 0.11 1.29 ± 0.12 < 0.001 Ham-D score 17.97 ± 0.358 2.25 ± 0.209 < 0.001     Male (P/C:65/59) 17.17 ± 0.56 2.49 ± 0.43 < 0.001     Female (P/C:140/136) 18.34 ± 0.45 2.15 ± 0.23 < 0.001 Serum leptin (ng/ml) 62.83 ± 4.28 69.74 ± 3.85 0.231     Male (P/C:65/59) 74.38 ± 9.67 73.52 ± 8.07 0.947     Female (P/C:140/136) 57.49 ± 4.32 68.10 ± 4.28 0.082 Serum EGF (pg/ml) 524.70 ± 27.25 672.52 ± 49.64 0.009     Male (P/C:65/59) 588.39 ± 56.07 519.65 ± 56.29 0.390     Female (P/C:140/136) 495.13 ± 30.06 738.84 ± 66.18 0.001 Abbreviations: BMI, body mass index, DSM-5, diagnostic and statistical manual for mental disorders, 5th edition; Ham-D, 17-item Hamilton depression rating scale; EGF, epithelial growth factor; MDD, major depressive disorder; P/C, patients/control; SEM, standard error mean. (p-value was determined by independent samples t-test) Discussion In this study, we investigated the involvement of EGF (a neurotrophic factor) and leptin (a pro-inflammatory cytokine) with MDD and depression severity. We measured the serum levels of leptin in MDD patients compared to HCs. The serum leptin levels were lower in MDD patients than HCs, but the alteration was not significant (p = 0.231). Though many research has been conducted to determine the relationship between leptin and depression, a concrete association was not established yet. A few case-control studies have suggested that reduced serum leptin levels are observed in depressive patients [38–40]. However, few other studies suggested that leptin levels were higher in depressive patients than in control subjects [42, 50]. Clinical research revealed that elevated serum leptin levels in young people with major depression were linked with the degree of depression [51]. Comparatively, a few case-control investigations on MDD patients failed to detect any appreciable alteration in leptin levels. The ambiguous relationship between serum leptin levels and depression was also supported by a meta-analysis of depression [44–46]. The fact that some variables, including sex, age, body mass status, sample sizes, and co-morbidity with other illnesses, impact serum leptin levels and these variables could be one of the reasons for the discrepant results. Another reason could be that leptin alteration may only be present in a subset of people who are depressive [52]. On the other hand, in this study, we also measured the serum levels of EGF in MDD patients compared to HCs. We found a significant decrease in EGF levels among MDD patients (p = 0.009). A substantial increase in DSM-5 score was also observed in MDD patients, as expected (p<0.001). Similarly, the HAM-D score was also higher in MDD patients than HCs, and the value was statistically significant (p<0.001). So, it could be assumed that there might be a relation between the HAM-D score and serum EGF concentration as their values increased and decreased, respectively, in MDD patients against healthy populations. But the Pearson correlation study showed that the serum EGF levels and the severity of depression were not inversely proportional (r = -0.064, p = 0.364). On the other hand, the association of EGF levels with depression was shown a very few studies. The levels of EGF in people with MDD have been the subject of a case-control preliminary inquiry. The serum EGF levels have been shown to be lower in MDD patients than in HCs [22]. Another study that compared serum concentrations of EGF levels between depressive patients and healthy subjects concluded that there was no noticeable change [48]. In contrast, another case-control investigation discovered increased EGF levels [47]. Furthermore, from sex-specific scatter plot graph where the distribution of serum EGF levels (pg/ml) against HAM-D score was depicted, it could be observed that the EGF levels were decreased in females more with the depression severity compared to males. After laboratory analysis, it was observed that the HAM-D score was higher in females than in males. At the same time, it was proven that serum EGF levels were lower in MDD females when compared to MDD males. But there was no significant correlation between sex and EGF levels. Moreover, to the best of our knowledge, this investigation is the first attempt in Bangladesh to find out the involvement of serum leptin and EGF levels with depression and to find out their association with the severity of depression. Under the same experimental conditions, simultaneous serum leptin and EGF levels were measured in MDD patients and HCs. In addition, the levels of leptin and EGF in the blood of MDD patients were examined according to sex. The results of this investigation will help to determine the depression risk in the future. At the same time, this study will add extra value to the knowledge resources in understanding the pathophysiology of major depression. Despite several notable findings, our study has certain limitations. The serum levels of leptin and EGF were measured once after enrolling them. Measuring the serum leptin and EGF levels alone cannot accurately represent the entire neuroinflammatory process of major depressive disorder. It would help to understand the pathophysiology of MDD more accurately when measuring other parameters in the same demographic and laboratory settings [53, 54]. Moreover, the duration of depression, that could potentially influence the levels of inflammatory parameters was not considered. The dietary habits of study populations, along with sleeping patterns, use of current medicines, or tobacco use, should have been taken into serious consideration in this present study, which might have an effect in altering serum leptin and EGF levels. Further investigation is suggested using larger samples, repeated measurements, and addressing this study’s limitations. Conclusion In this investigation, it was shown that there was a relationship between serum EGF levels and major depression. But involvement of the HAM-D score with serum EGF levels was not found in our investigation, thus a bridge between the severity of depression and EGF concentration could not be established. On the other hand, the involvement of leptin was not found in this study. Thus, after considering this study’s findings as a possible candidate for depression and a risk indicator of MDD, we would like to suggest EGF. The results of this study might be helpful in managing MDD in the future. It is advised that larger sample sizes be used in future studies. Authors are thankful to participants of this study. They would like to thank the administrative staff and physicians of the department of psychiatry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, for their cooperation to this study. 10.1371/journal.pone.0288159.r001 Decision Letter 0 Molla Md Maruf Ahmed Academic Editor © 2023 Md Maruf Ahmed Molla 2023 Md Maruf Ahmed Molla https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version0 24 Apr 2023 PONE-D-23-05701Reduced serum EGF but not leptin levels are associated with the pathophysiology of major depressive disorder: A case-control studyPLOS ONE Dear Dr. Islam, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR:I have reviewed all the comments from reviewers and i think this paper requires "extensive modifications". I would invite the authors to submit a revised paper addressing all the comments from reviewers.  Please submit your revised manuscript by Jun 08 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Md Maruf Ahmed Molla Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at  https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and  https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.   Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following:  ● The name of the colleague or the details of the professional service that edited your manuscript ● A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file) ● A clean copy of the edited manuscript (uploaded as the new *manuscript* file) [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know Reviewer #3: Yes Reviewer #4: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript is developed with an interesting subject Lots of Acronyms used without elaboration In title the acronym should be avoided The abstract start with MDD is not understanding for many of the readers In abstract the objective is not clearly mentioned The result section is very small, need to be elaborated The Odds Ratio (OR) is not analysed in the manuscript, but for case control study it is essential Reviewer #2: Dear authors, Congratulations on your hard work. However, I have some observations that may help with your manuscript. 1. Title: you have stated the result in the title. I might suggest to keep it minimum, like- Association of Reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study 2. Abstract, background, line 3: please rephrase the line: this study, we compared the serum levels of ' pro-inflammatory cytokine leptin and neurotrophic factor EGF' of healthy controls (HCs) and MDD patients. 3. Abstract, and background: please avoid abbrivations in the abstract. Also state the full term of MDD in the first line of background.. 4. Rephrase the line: On the one hand, trauma regarding 'physical, emotional, or sexual abuse' during childhood might also be a contributing factor to MDD 5. Please add some prevalence of MDD in Bangladeshi background also 6. In background, add the rationale of exploring EGF and leptin level in MDD in practical purpouse. Will they help in the treatment of MDD? 7. Methods: State the hypothesis if you have any 8. Methods: add brief description about HAM-D scale. How it is calculated/scored 9. Discussion: state the possible practical application of your finding at the end of discussion 10. Table 1 & 2: state the statistical tests used to determine the p value under the tables Reviewer #3: Thank you for inviting me to review the research paper titled “Reduced serum EGF but not leptin levels are associated with the pathophysiology of major depressive disorder: A case-control study “ I am writing to share my accepting of this study on the pathophysiology of depression. The research sheds important light on the complex mechanisms underlying depression and makes a significant contribution to the field. Even though the findings are still controversial and inconclusive yet but I commend the authors on the scientific rigor and meticulousness with which they presented the discussion, conclusions, recommendations, and limitations. Their attention to detail and thoughtful analysis demonstrate a deep understanding of the complexities of depression and reflect noted expertise and commitment to advancing the field. These findings have the potential to help future research and improve our understanding of depression, ultimately leading to better treatments and outcomes for those affected. Well done, Reviewer #4: The current manuscript aims to investigate whether the EGF and Leptin serum levels differ in MDD group from HCs. While I think that the research idea is very interesting, some changes seem to be essential for improving the academic quality of manuscript. Please see my comments below. Anyway, be it for resubmission in this journal or a submission to a different journal, I think the manuscript can be strengthened on condition of major revisions concerning all parts of the manuscript. I wish the authors the best of luck with this and their future research. Introduction 1- The writing style of Reference 1,2,3. etc.. seem not to meet to reference rules..( All references need to be reviewed. 2- Many of the cited articles are rather old and there is newer evidence that should be considered and given the credit it deserves, for instance 10, 21-24, 25, 27-29, 31..( I strongly recommend that the references be reviewed for currency) 3- “According to a survey report, the prevalence of MDD in a calendar year varied by country, which is about 2.20% and 10.40% in Japan and Brazil, respectively. Another study has revealed that people from middle-income nations are more affected by MDD than people from high-income nations.” “All of those hypotheses are supported by investigations regarding mental stress and findings about an increase in the level of hormones released due to stress like a CRH (corticotropin-releasing hormone), reduction in the availability of neurotransmitters, e.g., dopamine, noradrenaline, and serotonin in the synaptic cleft, alteration in the levels of inhibitory and excitatory neurotransmitters such as GABA, glutamate, respectively.” can you provide a reference supporting these claims? 4- I think that the authors did not provide enough rationale for why they focused on EGF and Leptin together. As far as it is understood from the last 2 paragraphs, they preferred to emphasize only discrepancy, but the presence of contradictions in the relationship between pro- and anti-inflammatory parameters and depression in general seems to make this background somewhat inadequate. Indeed, to the extent that it is essential to consider the two parameters together, the authors should propose a solution to the problem of multiple comparisons (type-II error) in the analyses in which they are included as dependent variables. The section on the epidemiology of depression in the first half seems to overshadow the intended message to some extent. Instead, I would have preferred to expand the framework on why Leptin and EGF were included together, and a separate paragraph on the hypotheses would have made it easier for readers. If the authors take this route, I believe that whether they present their hypotheses on Leptin and EGF as the same or separately will influence the results of the study. Method 1- The authors should indicate which treatments they excluded with the statement "Patients undergoing any therapy that could affect the concentration of serum leptin and EGF levels". For example, if they included the cases under antidepressant treatments, is the association with these two parameters at a level that requires to be considered as a control factor? Adding the basics of these to the "Introduction" would have complemented the biological framework of the article. Results 1- Table 2 shows that among male participants, serum EGF levels did not differ statistically from HC in MDD patients. The authors seem to have no indication of a gender effect, which I recommend controlling for in a model. 2- The information displayed in Table 1 seems to be (at least) redundant to the text in the Results part. Please decide whether you want to report it either in the main text, or in the table, but not both. 3- Adding correlation slopes in the scatter plot would make the visualization more meaningful. Also, I don't think the scatter plot is the appropriate graph to understand the “more severe depression levels of female MDDs”. Presenting the correlation coefficients in the text or in the graph will achieve the main goal here. 4- In addition, the characteristics of the study population are still given more space than the main results, and if they are to be presented in the text, it is more appropriate to summarize them. Instead, I suggest adding the points I mentioned to the main results. Discussion I assume that there might be a few changes to the discussion part based on my comments on the other parts, so I refrain from repeating my previously stated thoughts for all other parts of the manuscript and just focus on some additional comments I had for preparing a revision. 1- In the first paragraph, the authors begin the discussion section with a theoretical background that they have already included in the introduction. This seems to cause some disconnection in the narrative flow. Instead, I would suggest that the second paragraph should be placed first and the framework in the first paragraph should still be used in other parts of the discussion if necessary. I also think it is important that they state the extent to which the hypotheses I suggest to be presented in the introduction have been confirmed. 2- The statements in paragraph 3 “On the one hand, in this study, we also measured the serum levels of EGF in MDD patients compared to HCs. We found a significant decrease in EGF levels among MDD patients (p=0.009). A substantial increase in DSM-5 score was also observed in MDD patients, as expected (p<0.001) …...” do not infer a correlation between HAM-D and EGF concentration. It is essential to conduct the correlation analysis itself, rather than interpreting the results that allegedly lead to the inference of correlation. 3- From the statements in paragraph 4 “Furthermore, from sex-specific scatter plot graph where the distribution of serum EGF levels (pg/ml) against Ham-D score was depicted, it could be observed that the severity of depression was higher in females compared to males. After laboratory analysis, it was observed that the Ham-D score was higher in females than males, and the score difference between female subjects was higher than the score difference between male subjects. At the same time, serum EGF levels were lower in MDD females when compared to MDD males.”, it is clear that the authors have only made an observational interpretation. The statement that EGF causes depression more in women sounds ambitious on several counts. First, since the study design is cross-sectional, causality between variables cannot be established. The other is that the EGF concentration-severity of depression-gender relationship suggested by the authors can only be confirmed/falsified within an interaction model (e.g. factorial analysis of variance). 4- Limitation: I would expact that the authors add to the limitations that the duration of depression that could potentially influence the levels of inflammatory parameters. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 10.1371/journal.pone.0288159.r002 Author response to Decision Letter 0 Submission Version1 8 Jun 2023 Uploaded as separate file. Attachment Submitted filename: Response to Reviewers.docx Click here for additional data file. 10.1371/journal.pone.0288159.r003 Decision Letter 1 Molla Md Maruf Ahmed Academic Editor © 2023 Md Maruf Ahmed Molla 2023 Md Maruf Ahmed Molla https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Submission Version1 20 Jun 2023 Association of reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study PONE-D-23-05701R1 Dear Dr. Islam, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Md Maruf Ahmed Molla Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 10.1371/journal.pone.0288159.r004 Acceptance letter Molla Md Maruf Ahmed Academic Editor © 2023 Md Maruf Ahmed Molla 2023 Md Maruf Ahmed Molla https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 26 Jun 2023 PONE-D-23-05701R1 Association of reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study Dear Dr. Islam: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Md Maruf Ahmed Molla Academic Editor PLOS ONE ==== Refs References 1 Belmaker RH , Agam G . Major depressive disorder. N Engl J Med. 2008;358 (1 ):55–68. doi: 10.1056/NEJMra073096 18172175 2 Otte C , Gold SM , Penninx BW , et al . Major depressive disorder. Nat Rev Dis Primers. 2016;2 :16065. Published 2016 Sep 15. doi: 10.1038/nrdp.2016.65 27629598 3 Flint J , Kendler KS . The genetics of major depression [published correction appears in Neuron. 2014 Mar 5;81(5):1214]. Neuron. 2014;81 (3 ):484–503. doi: 10.1016/j.neuron.2014.01.027 24507187 4 Rahman S , Shanta AA , Daria S , et al . Increased serum resistin but not G-CSF levels are associated in the pathophysiology of major depressive disorder: Findings from a case-control study. PLoS One. 2022;17 (2 ):e0264404. Published 2022 Feb 25. doi: 10.1371/journal.pone.0264404 35213631 5 Nishuty NL , Khandoker MMH , Karmoker JR , et al . Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients. Cureus. 2019;11 (1 ):e3868. Published 2019 Jan 11. doi: 10.7759/cureus.3868 30899619 6 Riya S , Sultana S , Daria S , et al . Evaluation of Serum Lysophosphatidic Acid and Lysophosphatidylcholine Levels in Major Depressive Disorder Patients. Cureus. 2020;12 (12 ):e12388. Published 2020 Dec 30. doi: 10.7759/cureus.12388 33542861 7 Lorant V , Deliège D , Eaton W , Robert A , Philippot P , Ansseau M . Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157 (2 ):98–112. doi: 10.1093/aje/kwf182 12522017 8 Li M , D’Arcy C , Meng X . Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: systematic review, meta-analysis, and proportional attributable fractions. Psychol Med. 2016;46 (4 ):717–730. doi: 10.1017/S0033291715002743 26708271 9 Islam MR , Islam MR , Ahmed I , et al . Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study. SAGE Open Med. 2018;6 :2050312118773953. Published 2018 May 9. doi: 10.1177/2050312118773953 29770218 10 Whooley MA , Wong JM . Depression and cardiovascular disorders. Annu Rev Clin Psychol. 2013;9 :327–354. doi: 10.1146/annurev-clinpsy-050212-185526 23537487 11 Hasin DS , Sarvet AL , Meyers JL , et al . Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018;75 (4 ):336–346. doi: 10.1001/jamapsychiatry.2017.4602 29450462 12 Seedat S , Scott KM , Angermeyer MC , et al . Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry. 2009;66 (7 ):785–795. doi: 10.1001/archgenpsychiatry.2009.36 19581570 13 Kessler RC , Birnbaum HG , Shahly V , et al . Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety. 2010;27 (4 ):351–364. doi: 10.1002/da.20634 20037917 14 Kessler RC , Bromet EJ . The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34 :119–138. doi: 10.1146/annurev-publhealth-031912-114409 23514317 15 Ogbo FA , Mathsyaraja S , Koti RK , Perz J , Page A . The burden of depressive disorders in South Asia, 1990–2016: findings from the global burden of disease study. BMC Psychiatry. 2018;18 (1 ):333. Published 2018 Oct 16. doi: 10.1186/s12888-018-1918-1 30326863 16 Chesney E , Goodwin GM , Fazel S . Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13 (2 ):153–160. doi: 10.1002/wps.20128 24890068 17 Nahar Z , Sal-Sabil N , Sohan M , Qusar MS , Islam MR . Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: A case-control study results. Health Sci Rep. 2022;6 (1 ):e1005. Published 2022 Dec 24. doi: 10.1002/hsr2.1005 36582626 18 Islam S , Islam T , Nahar Z , et al . Altered serum adiponectin and interleukin-8 levels are associated in the pathophysiology of major depressive disorder: A case-control study. PLoS One. 2022;17 (11 ):e0276619. Published 2022 Nov 21. doi: 10.1371/journal.pone.0276619 36409748 19 Duman RS , Sanacora G , Krystal JH . Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102 (1 ):75–90. doi: 10.1016/j.neuron.2019.03.013 30946828 20 Islam MR , Ali S , Karmoker JR , et al . Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020;20 (1 ):333. Published 2020 Jun 24. doi: 10.1186/s12888-020-02738-2 32580709 21 Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry. 2010;9 (3 ):155–161. doi: 10.1002/j.2051-5545.2010.tb00298.x 20975857 22 Tian W , Zhang J , Zhang K , et al . A study of the functional significance of epidermal growth factor in major depressive disorder. Psychiatr Genet. 2012;22 (4 ):161–167. doi: 10.1097/YPG.0b013e3283539550 22504456 23 Duman RS . Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry. 2002;17 Suppl 3 :306–310. doi: 10.1016/s0924-9338(02)00654-5 15177086 24 Manji HK , Moore GJ , Chen G . Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48 (8 ):740–754. doi: 10.1016/s0006-3223(00)00979-3 11063971 25 Fekri K , Nayebi AM , Sadigh-Eteghad S , et al . The neurochemical changes involved in immobilization stress-induced anxiety and depression: Roles for oxidative stress and neuroinflammation. Neurochemical Journal. 2020;14 :133–149. 26 de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun. 2002;16 (5 ):610–617. doi: 10.1016/s0889-1591(02)00005-3 12401476 27 Lotrich FE . Inflammatory cytokine-associated depression. Brain Res. 2015;1617 :113–125. doi: 10.1016/j.brainres.2014.06.032 25003554 28 Raison CL , Borisov AS , Majer M , et al . Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65 (4 ):296–303. doi: 10.1016/j.biopsych.2008.08.010 18801471 29 Hoyo-Becerra C , Schlaak JF , Hermann DM . Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun. 2014;42 :222–231. doi: 10.1016/j.bbi.2014.06.200 25066466 30 Sutcigil L , Oktenli C , Musabak U , et al . Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol. 2007;2007 :76396. doi: 10.1155/2007/76396 18317531 31 You Z , Luo C , Zhang W , et al . Pro- and anti-inflammatory cytokines expression in rat’s brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res. 2011;225 (1 ):135–141. doi: 10.1016/j.bbr.2011.07.006 21767575 32 Young JJ , Bruno D , Pomara N . A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014;169 :15–20. doi: 10.1016/j.jad.2014.07.032 25128861 33 Ménard C , Hodes GE , Russo SJ . Pathogenesis of depression: Insights from human and rodent studies. Neuroscience. 2016;321 :138–162. doi: 10.1016/j.neuroscience.2015.05.053 26037806 34 Howren MB , Lamkin DM , Suls J . Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71 (2 ):171–186. doi: 10.1097/PSY.0b013e3181907c1b 19188531 35 Lord GM . Leptin as a proinflammatory cytokine. Contrib Nephrol. 2006;151 :151–164. doi: 10.1159/000095326 16929139 36 Ma K , Zhang H , Baloch Z . Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci. 2016;17 (5 ):733. Published 2016 May 14. doi: 10.3390/ijms17050733 27187381 37 Procaccini C , Jirillo E , Matarese G . Leptin as an immunomodulator. Mol Aspects Med. 2012;33 (1 ):35–45. doi: 10.1016/j.mam.2011.10.012 22040697 38 Eikelis N , Esler M , Barton D , Dawood T , Wiesner G , Lambert G . Reduced brain leptin in patients with major depressive disorder and in suicide victims. Mol Psychiatry. 2006;11 (9 ):800–801. doi: 10.1038/sj.mp.4001862 16936761 39 Kraus T , Haack M , Schuld A , Hinze-Selch D , Pollmächer T . Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology. 2001;73 (4 ):243–247. doi: 10.1159/000054641 11340338 40 Yang K , Xie G , Zhang Z , et al . Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatry. 2007;41 (3 ):266–273. doi: 10.1080/00048670601057759 17464708 41 Ge T , Fan J , Yang W , Cui R , Li B . Leptin in depression: a potential therapeutic target. Cell Death Dis. 2018;9 (11 ):1096. Published 2018 Oct 26. doi: 10.1038/s41419-018-1129-1 30367065 42 Milaneschi Y , Lamers F , Bot M , Drent ML , Penninx BW . Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. Biol Psychiatry. 2017;81 (9 ):807–814. doi: 10.1016/j.biopsych.2015.10.023 26742925 43 Antonijevic IA , Murck H , Frieboes RM , Horn R , Brabant G , Steiger A . Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res. 1998;32 (6 ):403–410. doi: 10.1016/s0022-3956(98)00032-6 9844957 44 Carvalho AF , Rocha DQ , McIntyre RS , et al . Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J Psychiatr Res. 2014;59 :28–37. doi: 10.1016/j.jpsychires.2014.08.002 25183029 45 Deuschle M , Blum WF , Englaro P , et al . Plasma leptin in depressed patients and healthy controls. Horm Metab Res. 1996;28 (12 ):714–717. doi: 10.1055/s-2007-979885 9013749 46 Jow GM , Yang TT , Chen CL . Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord. 2006;90 (1 ):21–27. doi: 10.1016/j.jad.2005.09.015 16324751 47 Skibinska M , Kapelski P , Dmitrzak-Weglarz M , et al . Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders-Longitudinal Study in Adolescent and Young Adult Patients. J Clin Med. 2021;10 (18 ):4064. Published 2021 Sep 8. doi: 10.3390/jcm10184064 34575175 48 Wu HE , Teixeira AL , Barroso L , et al . Epidermal growth factor and fibroblast growth factor-2 circulating levels in elderly with major depressive disorder. Psychiatry Res. 2019;272 :141–143. doi: 10.1016/j.psychres.2018.12.084 30583255 49 Ménard C , Hodes GE , Russo SJ . Pathogenesis of depression: Insights from human and rodent studies. Neuroscience. 2016;321 :138–162. doi: 10.1016/j.neuroscience.2015.05.053 26037806 50 Esel E , Ozsoy S , Tutus A , et al . Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29 (4 ):565–570. doi: 10.1016/j.pnpbp.2005.01.009 15866359 51 Steiner J , Dobrowolny H , Guest PC , et al . Plasma Anthranilic Acid and Leptin Levels Predict HAM-D Scores in Depressed Women. Int J Tryptophan Res. 2021;14 :11786469211016474. Published 2021 May 19. doi: 10.1177/11786469211016474 34045868 52 Lu XY . The leptin hypothesis of depression: a potential link between mood disorders and obesity?. Curr Opin Pharmacol. 2007;7 (6 ):648–652. doi: 10.1016/j.coph.2007.10.010 18032111 53 Salsabil L , Shahriar M , Islam SMA , Bhuiyan MA , Qusar MS , Islam MR . Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case-control study. J Int Med Res. 2023;51 (4 ):3000605231166222. doi: 10.1177/03000605231166222 37038918 54 Nahar Z , Monisha ST , Qusar MS , Islam MR . Evaluation of serum interleukin-1 receptor antagonist levels in major depressive disorder: A case-control study. Health Sci Rep. 2023;6 (4 ):e1175. Published 2023 Mar 29. doi: 10.1002/hsr2.1175 37008817